Related Articles

• Vorinostat enhances gefitinib‑induced cell death through reactive oxygen species‑dependent cleavage of HSP90 and its clients in non‑small cell lung cancer with the EGFR mutation
• Shikonin sensitizes wild‑type EGFR NSCLC cells to erlotinib and gefitinib therapy
• Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations
• Schedule-dependent antitumor activity of the combination with erlotinib and docetaxel in human non-small cell lung cancer cells with EGFR mutation, KRAS mutation or both wild-type EGFR and KRAS
• Continuous exposure of non‑small cell lung cancer cells with wild‑type EGFR to an inhibitor of EGFR tyrosine kinase induces chemoresistance by activating STAT3